Copyright
©The Author(s) 2024.
World J Gastroenterol. Feb 21, 2024; 30(7): 644-651
Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.644
Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.644
Figure 3 First-line treatment for metastatic colon and rectal cancer patients.
anti-EGFR: Anti-epidermal growth factor receptor agent; dMMR/MSI-H: Deficient mismatch repair/microsatellite instability; FOLFOX: 5-fluorouracil + oxaliplatin; FOLFOXIRI: 5-fluorouracil + oxaliplatin + irinotecan; FOLFIRI: 5-fluorouracil + irinotecan; mut: Mutant; XELOX: Capecitabine + oxaliplatin; wt: Wild-type; BRAF: B-raf proto-oncogene.
- Citation: Pinheiro M, Moreira DN, Ghidini M. Colon and rectal cancer: An emergent public health problem. World J Gastroenterol 2024; 30(7): 644-651
- URL: https://www.wjgnet.com/1007-9327/full/v30/i7/644.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i7.644